|
Mutation Information
|
Mutation Site
|
E138K |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Combined Mutation
|
in.E138K+in.R263K |
|
Relevant Drug
|
dolutegravir (DTG) |
Literature Information
|
PubMed PMID
|
25394027
|
|
Published Year
|
2014 |
|
Journal
|
Journal of the International AIDS Society |
|
Title
|
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. |
|
Author
|
Wainberg M,Anstett K,Mesplede T,Quashie P,Han Y,Oliveira M |
|
Evidence
|
Secondary mutations selected at positions H51Y or E138K did not individually affect either enzyme activity or DTG resistance, but the combination of R263K together with H51Y or E138K increased DTG resistance to about 7-fold accompanied by a approximately 75% loss in each of viral replication capacity, and both in vitro and in vivo integrase activity.
|
|
|
HIV Mutation Detail Information